EMAIL THIS PAGE TO A FRIEND

Alimentary pharmacology & therapeutics

Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.


PMID 25186086

Abstract

In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and presumably associated with increased mortality and cardiovascular risk. To evaluate the prognostic value of non-invasive biomarkers of liver fibrosis (FibroTest) and steatosis (SteatoTest) in patients with type-2 diabetes and/or dyslipidaemia. A total of 2312 patients with type-2 diabetes and/or dyslipidaemia were included and prospectively followed up for 5-15xa0years. The cardiovascular Framingham-risk score was calculated; advanced fibrosis and severe steatosis, were defined by FibroTest >0.48 and SteatoTest >0.69, respectively, as previously established. During a median follow-up of 12xa0years, 172 patients (7.4%) died. The leading causes of mortality were cancer (31%) and cardiovascular-related death (20%). The presence of advanced fibrosis [HR (95% CI)] [2.98 (95% CI 1.78-4.99); Pxa0

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

B4126
Bilirubin, ≥98% (EmM/453 = 60), powder
C33H36N4O6